Navigation Links
MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Date:12/13/2007

VANCOUVER and SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended October 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study being conducted by our development and commercialization partner Cadence Pharmaceuticals is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial. Cadence expects they will complete enrollment of the 1,850 patients planned for the trial in the second quarter of 2008, with results available in the second half of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit a New Drug Application ("NDA") for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II 12-week combination therapy study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

In conjunct
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... InferMed , s decision ... augment Elsevier ... suite   Elsevier , a world-leading provider ... today the acquisition of  InferMed , a London ... InferMed,s Arezzo technology supports clinicians in choosing the most appropriate ...
(Date:7/1/2015)... ... 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks can ... Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original Equipment ... increase healthcare worker safety and reduce financial costs. , CTI Electronics announces a ...
(Date:6/30/2015)... , July 1, 2015 R-Japan Co.,Ltd. obtained ... the Safety of Regenerative Medicine from the Ministry of Health, ... June 29, 2015. The fact that R- ... facility through the auditing from Pharmaceuticals and Medical Devices Agency ... application, allows it to provide stem cell manufacturing service to ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... , KENILWORTH, N.J., Aug. 26 Schering-Plough ... European Medicines Agency (EMEA) has validated (accepted for review) the ... mometasone furoate and formoterol fumarate for the maintenance treatment of ... The company also announced today that the EMEA has validated ...
... N.C., Aug. 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... New York on Sept. 9 and Zurich on Sept. 10, 2009. ... Division and Government Affairs, will present at the Rodman & Renshaw ... at 2:00 p.m. eastern time. , , A ...
... , ... Trusted LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons directory service and website ... to improve their vision and find a highly qualified eye surgeon who can ... apart is a unique screening process ensuring that only those who are among ...
Cached Biology Technology:Schering-Plough Announces Two European Filings 2Schering-Plough Announces Two European Filings 3Schering-Plough Announces Two European Filings 4Schering-Plough Announces Two European Filings 5Schering-Plough Announces Two European Filings 6Schering-Plough Announces Two European Filings 7Schering-Plough Announces Two European Filings 8Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich 2LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 2LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 3LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 4LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 5LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 6LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 7
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards has ... sensors in the company,s portfolio from one of its module ... to mainly take place during the third quarter 2015. The ... Asia . Jörgen Lantto, CEO of FPC, ... the   growing interest from smartphone OEMs in integrating touch ...
(Date:6/15/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces that its leading payment security technology, the ... Experience! @ NYC June 18th. Digital Experience! @ ... in technology to over 300 of the top media covering ... Pavilion in New York City from ...
(Date:6/9/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, will be providing demonstrations of its ... Drug Information Association (DIA) Annual Meeting in ... will include previews of many exciting new enhancements that ... iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... Researchers have teased out the molecular process that can ... kills thousands each year who suffer battlefield casualties, heart ... an article published in the January edition of ... the enormously complex biomechanics of a reaction first observed ...
... The National Institute of Allergies and Infectious Diseases (NIAID), ... awarded a five-year contract totaling $15,254,919 to Tulane University ... fever, an often deadly viral disease that threatens hundreds ... is classified as a potential bioterrorism threat. The ...
... Iowa -- A previous six-month study by Iowa State ... soy protein, rich in isoflavones, lessened lumbar spine bone ... three-year study by some of those same researchers does ... ingested soy isoflavone tablets, except for a modest effect ...
Cached Biology News:Research could lead to way to halt deadly immune response 2Research could lead to way to halt deadly immune response 3Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 2Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 3
... Mass Spectrometry Applications ,In the age ... emerged as a powerful protein identification and ... is now an important intermediate step in ... to identification of specific proteins in the ...
... the only PCR system that ensures successful ... It provides accuracy, consistency, and dependability for ... property of the DNA templates. This system ... unique blend of thermostable enzymes that is ...
... Application: A cleaning agent ... plastic surfaces, countertops, and pipettors. ... at eliminating RNase contamination from ... enzymatic reactions. ,RNase Zap ...
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: